Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) reports positive CAN10 update
Published by Arron Aatkar, PhD

Cantargia has reported encouraging pharmacokinetic data from the first cohort in the multiple ascending dose portion of the CAN10 study. Importantly, the data align with the single dose portion of the programme and further support continuation at four-weekly dosing. Additionally, the FDA has provided positive feedback on Cantargia’s plans for the design of a Phase II trial in hidradenitis suppurativa (often referred to as HS). This decision has been backed by a scientific advisory board comprising key opinion leaders in the field. Preparations for Phase II are ongoing, and management expects to submit an investigational new drug application in H225.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free